These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6126371)

  • 1. Modification of cardiovascular actions of 2-amino-5,6-dihydroxytetralin by N,N-di-n-propyl substitution.
    Kohli JD; Goldberg LI; McDermed JD
    Eur J Pharmacol; 1982 Jul; 81(2):293-9. PubMed ID: 6126371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective DA2 versus DA1 antagonist activity of domperidone in the periphery.
    Kohli JD; Glock D; Goldberg LI
    Eur J Pharmacol; 1983 Apr; 89(1-2):137-41. PubMed ID: 6861882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the enantiomers of 3-PPP on DA1 and DA2 dopamine receptors in the dog.
    Kohli JD; Glock D; Goldberg LI
    Eur J Pharmacol; 1985 Aug; 114(3):305-10. PubMed ID: 4065203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine vascular actions of N-substituted derivatives of 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene (ADTN).
    Kohli JD; Goldberg LI; Nichols DE
    Eur J Pharmacol; 1979 Jun; 56(1-2):39-44. PubMed ID: 467513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Separation of peripheral dopamine receptors by a selective DA1 antagonist, SCH 23390.
    Goldberg LI; Glock D; Kohli JD; Barnett A
    Hypertension; 1984; 6(2 Pt 2):I25-30. PubMed ID: 6144634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential activation by some 2-aminotetralin derivatives of the receptor mechanisms in the nucleus accumbens of rats which mediate hyperactivity and stereotyped biting.
    Costall B; Naylor RJ; Cannon JG; Lee T
    Eur J Pharmacol; 1977 Feb; 41(3):307-19. PubMed ID: 556988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin suppressive effects of aminotetralin analogs and of dopamine.
    Blum JW
    Eur J Pharmacol; 1984 Oct; 105(3-4):239-44. PubMed ID: 6391938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central and peripheral dopaminergic mechanisms in the cardiovascular actions of pergolide in neurogenic hypertensive dogs.
    Barrett RJ; Lokhandwala MF
    Eur J Pharmacol; 1983 Dec; 96(3-4):211-26. PubMed ID: 6676105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational requirements for dopamine-induced vasodilation.
    Volkman PH; Kohli JD; Goldberg LI; Cannon JG; Lee T
    Proc Natl Acad Sci U S A; 1977 Aug; 74(8):3602-6. PubMed ID: 269416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N,N-Di-n-propyl dopamine: a qualitatively different dopamine vascular agonist.
    Kohli JD; Goldberg LI; Volkman PH; Cannon JG
    J Pharmacol Exp Ther; 1978 Oct; 207(1):16-22. PubMed ID: 702336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consistent unmasking of dopamine-induced dilation of the canine femoral vascular bed.
    Listinsky JJ; Kohli JD; Goldberg LI
    J Pharmacol Exp Ther; 1980 Dec; 215(3):662-7. PubMed ID: 6108364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
    Gorczynski RJ; Anderson WG; Stout DM
    J Med Chem; 1981 Jul; 24(7):835-9. PubMed ID: 7277389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological profile of N,N dipropyl-8-hydroxy-3-chromanamine, an oxygen isostere of the dopamine agonist N,N dipropyl-5-hydroxy-2-aminotetralin with enhanced presynaptic selectivity.
    Vermue NA; Kaptein B; Tepper PG; de Vries JB; Horn AS
    Arch Int Pharmacodyn Ther; 1988; 293():37-56. PubMed ID: 3421784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presynaptic effects of 2-aminotetralins on striatal dopaminergic neurons.
    Hoffmann IS; Naylor RJ; Cubeddu LX
    J Pharmacol Exp Ther; 1980 Nov; 215(2):486-93. PubMed ID: 7441511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular and renal hemodynamic effects of intravenous infusions of the selective DA1 agonist, fenoldopam, used alone or in combination with dopamine and dobutamine.
    Lass NA; Glock D; Goldberg LI
    Circulation; 1988 Nov; 78(5 Pt 1):1310-5. PubMed ID: 2902941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha 1/alpha 2-adrenoceptor agonist selectivity of mono- and dihydroxy-2-N,N-DI-n-propylaminotetralins.
    Timmermans PB; Mathy MJ; Wilffert B; Kalkman HO; Smit G; Dijkstra D; Horn AS; Van Zwieten PA
    Eur J Pharmacol; 1984 Jan; 97(1-2):55-65. PubMed ID: 6321211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of dopamine, N-N-di-n-propyl dopamine, and (R)- and (S)-sulpiride on guinea pig blood pressure.
    Horn PT; Kohli JD; Goldberg LI
    J Cardiovasc Pharmacol; 1982; 4(4):668-75. PubMed ID: 6181343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose related sequence of effects induced by the DA agonist 2-(N,N-dipropyl)-amino-5,6-dihydroxytetralin.
    Doaré L; Puech AJ; Simon P
    J Pharmacol; 1986; 17(1):60-4. PubMed ID: 3713199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the cardiovascular actions of dopamine and epinine in the dog.
    Itoh H; Kohli JD; Rajfer SI; Goldberg LI
    J Pharmacol Exp Ther; 1985 Apr; 233(1):87-93. PubMed ID: 2858584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bulbocapnine is not a selective DA1 receptor antagonist.
    Kohli JD; Glock D; Goldberg LI
    J Pharm Pharmacol; 1986 May; 38(5):401-2. PubMed ID: 2872323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.